image
Healthcare - Biotechnology - NASDAQ - US
$ 9.48
-2.17 %
$ 816 M
Market Cap
-2.46
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one SNDX stock under the worst case scenario is HIDDEN Compared to the current market price of 9.48 USD, Syndax Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one SNDX stock under the base case scenario is HIDDEN Compared to the current market price of 9.48 USD, Syndax Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one SNDX stock under the best case scenario is HIDDEN Compared to the current market price of 9.48 USD, Syndax Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SNDX

image
$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
23.7 M REVENUE
0.00%
-340 M OPERATING INCOME
-47.71%
-319 M NET INCOME
-52.25%
-275 M OPERATING CASH FLOW
-71.17%
-220 M INVESTING CASH FLOW
-186.87%
353 M FINANCING CASH FLOW
33.78%
20 M REVENUE
160.96%
-83.8 M OPERATING INCOME
13.08%
-84.8 M NET INCOME
9.90%
-95.2 M OPERATING CASH FLOW
-65.82%
94.1 M INVESTING CASH FLOW
135.00%
930 K FINANCING CASH FLOW
-99.73%
Balance Sheet Syndax Pharmaceuticals, Inc.
image
Current Assets 603 M
Cash & Short-Term Investments 573 M
Receivables 11.2 M
Other Current Assets 18.9 M
Non-Current Assets 122 M
Long-Term Investments 120 M
PP&E 2.02 M
Other Non-Current Assets 217 K
79.04 %16.49 %Total Assets$724.8m
Current Liabilities 104 M
Accounts Payable 11.6 M
Short-Term Debt 12.6 M
Other Current Liabilities 79.3 M
Non-Current Liabilities 333 M
Long-Term Debt 1.58 M
Other Non-Current Liabilities 332 M
2.88 %18.17 %75.93 %Total Liabilities$436.7m
EFFICIENCY
Earnings Waterfall Syndax Pharmaceuticals, Inc.
image
Revenue 23.7 M
Cost Of Revenue 826 K
Gross Profit 22.9 M
Operating Expenses 363 M
Operating Income -340 M
Other Expenses -20.9 M
Net Income -319 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)24m(826k)23m(363m)(340m)21m(319m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
96.51% GROSS MARGIN
96.51%
-1434.43% OPERATING MARGIN
-1434.43%
-1346.11% NET MARGIN
-1346.11%
-110.63% ROE
-110.63%
-43.98% ROA
-43.98%
-53.59% ROIC
-53.59%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Syndax Pharmaceuticals, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -319 M
Depreciation & Amortization 8 K
Capital Expenditures 0
Stock-Based Compensation 43 M
Change in Working Capital 0
Others 821 K
Free Cash Flow -275 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Syndax Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for SNDX of $30.5 , with forecasts ranging from a low of $18 to a high of $37 .
SNDX Lowest Price Target Wall Street Target
18 USD 89.87%
SNDX Average Price Target Wall Street Target
30.5 USD 221.73%
SNDX Highest Price Target Wall Street Target
37 USD 290.30%
Price
Max Price Target
Min Price Target
Average Price Target
404035353030252520201515101055Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 18
6. Ownership
Insider Ownership Syndax Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
454 K USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
242 K USD 4
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 – Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – globenewswire.com - 3 weeks ago
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 – 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ORR in Ph 1 patients with R/R NUP98r AML – NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced new data from the pivotal AUGMENT-101 trial of Revuforj® (revumenib), the Company's first-in-class menin inhibitor, in patients with relapsed or refractory (R/R) mutant NPM1 (mNPM1) and NUP98-rearranged (NUP98r) acute myeloid leukemia (AML). The data are being presented in posters at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy and virtually. globenewswire.com - 3 weeks ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2025 the Company granted inducement awards to purchase up to 119,700 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. globenewswire.com - 4 weeks ago
Syndax Announces Participation in June Investor Conferences NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: globenewswire.com - 1 month ago
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) – Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – globenewswire.com - 1 month ago
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer - Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - globenewswire.com - 1 month ago
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
Syndax Announces Participation in May Investor Conferences NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Bank of America Merrill Lynch Vegas Health Care Conference with a fireside chat on Thursday, May 15, 2025, at 9:20 a.m. globenewswire.com - 1 month ago
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood – Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML submitted in April 2025 – NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, a first-in-class menin inhibitor, in patients with relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) have been published in Blood. “We are thrilled to publish the first positive pivotal dataset in patients with an NPM1 mutation, the most common genetic alteration observed in AML,” said Neil Gallagher, M.D. globenewswire.com - 1 month ago
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Sharon Klahre - Head of IR Michael Metzger - Chief Executive Officer and Director Steve Closter - Chief Commercial Officer Neil Gallagher - President and Head of R&D Keith Goldan - Chief Financial Officer Anjali Ganguli - Chief Strategy Officer Conference Call Participants Jason Zemansky - Bank of America Ellen Horste - TD Cowen Peter Lawson - Barclays Michael Schmidt - Guggenheim David Dai - UBS Yigal Nochomovitz - Citi Kalpit Patel - B. Riley Securities Jeet Mukherjee - BTIG Salim Syed - Mizuho George Farmer - Scotiabank Operator Good day, everyone, and welcome to the Syndax First Quarter 2025 Earnings Conference Call. seekingalpha.com - 1 month ago
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.85 per share a year ago. zacks.com - 1 month ago
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update – $20.0 million in Revuforj ® (revumenib) net revenue in first full quarter of launch – globenewswire.com - 1 month ago
8. Profile Summary

Syndax Pharmaceuticals, Inc. SNDX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 816 M
Dividend Yield 0.00%
Description Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Contact 35 Gatehouse Drive, New York City, MA, 02451 https://www.syndax.com
IPO Date March 2, 2016
Employees 270
Officers Mr. Michael A. Metzger M.B.A. Chief Executive Officer & Director